Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Ellis

Showing results (21-30 of 285) with videos related to

Pageof 29
Sort By:
Cancer Discovery|January 16, 2013
The genomic landscape of breast cancer as a therapeutic roadmapMatthew J Ellis, Charles M Perou
Breast Cancer Research : BCR|September 20, 2005
Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathwayRobert J Crowder, Matthew J Ellis
Journal of the National Cancer Institute|March 31, 2011
Understanding the estrogen receptor-positive breast cancer genome: not even the end of the beginningBrian A Van Tine, Matthew J Ellis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
Reply to T. Reinert et alMatthew J Ellis, John F R Robertson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2017
Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast CancerRodrigo Goncalves, Tomás Reinert, Matthew J Ellis
Oncotarget|December 18, 2018
DNA damage repair defects as a new class of endocrine treatment resistance driverMeenakshi Anurag, Matthew J Ellis, Svasti Haricharan
Current Treatment Options in Oncology|April 18, 2018
Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast CancerTomás Reinert, Rodrigo Gonçalves, Matthew J Ellis
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 23, 2009
[Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer]Masakazu Toi, Hironobu Sasano, Matthew J Ellis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2019
CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?Meenakshi Anurag, Svasti Haricharan, Matthew J Ellis
Oncology (Williston Park, N.Y.)|September 11, 2012
The natural history of hormone receptor-positive breast cancer: attempting to decipher an intriguing conceptGayathri Nagaraj, Matthew J Ellis, Cynthia X Ma
Pageof 29

Showing results (21-30 of 285) with videos related to

Sort By:
Pageof 29
Cancer Discovery|January 16, 2013
The genomic landscape of breast cancer as a therapeutic roadmapMatthew J Ellis, Charles M Perou
Breast Cancer Research : BCR|September 20, 2005
Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathwayRobert J Crowder, Matthew J Ellis
Journal of the National Cancer Institute|March 31, 2011
Understanding the estrogen receptor-positive breast cancer genome: not even the end of the beginningBrian A Van Tine, Matthew J Ellis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
Reply to T. Reinert et alMatthew J Ellis, John F R Robertson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2017
Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast CancerRodrigo Goncalves, Tomás Reinert, Matthew J Ellis
Oncotarget|December 18, 2018
DNA damage repair defects as a new class of endocrine treatment resistance driverMeenakshi Anurag, Matthew J Ellis, Svasti Haricharan
Current Treatment Options in Oncology|April 18, 2018
Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast CancerTomás Reinert, Rodrigo Gonçalves, Matthew J Ellis
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 23, 2009
[Future prospects of neoadjuvant endocrine therapy in postmenopausal breast cancer]Masakazu Toi, Hironobu Sasano, Matthew J Ellis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2019
CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?Meenakshi Anurag, Svasti Haricharan, Matthew J Ellis
Oncology (Williston Park, N.Y.)|September 11, 2012
The natural history of hormone receptor-positive breast cancer: attempting to decipher an intriguing conceptGayathri Nagaraj, Matthew J Ellis, Cynthia X Ma
Pageof 29